Cantor Fitzgerald Weighs in on NuVasive, Inc.’s FY2019 Earnings (NUVA)
NuVasive, Inc. (NASDAQ:NUVA) – Analysts at Cantor Fitzgerald boosted their FY2019 earnings per share estimates for shares of NuVasive in a research report issued to clients and investors on Thursday, May 2nd. Cantor Fitzgerald analyst C. Bijou now expects that the medical device company will earn $2.27 per share for the year, up from their prior estimate of $2.21. Cantor Fitzgerald currently has a “Hold” rating and a $61.00 price objective on the stock.
A number of other brokerages have also commented on NUVA. Zacks Investment Research lowered shares of NuVasive from a “hold” rating to a “sell” rating in a report on Wednesday, February 13th. BTIG Research cut their price objective on shares of NuVasive to $59.00 and set a “buy” rating on the stock in a report on Thursday, January 17th. They noted that the move was a valuation call. Jefferies Financial Group lowered shares of NuVasive from a “buy” rating to a “hold” rating and set a $60.00 price objective on the stock. in a report on Tuesday, February 12th. Needham & Company LLC lowered shares of NuVasive from a “buy” rating to a “hold” rating in a report on Friday, February 8th. Finally, BidaskClub upgraded shares of NuVasive from a “sell” rating to a “hold” rating in a report on Thursday, April 25th. Two research analysts have rated the stock with a sell rating, eight have assigned a hold rating and eight have issued a buy rating to the company’s stock. The stock has a consensus rating of “Hold” and a consensus price target of $67.43.
NuVasive (NASDAQ:NUVA) last posted its earnings results on Wednesday, May 1st. The medical device company reported $0.53 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $0.41 by $0.12. The business had revenue of $274.78 million for the quarter, compared to analyst estimates of $269.22 million. NuVasive had a net margin of 4.39% and a return on equity of 15.16%. The business’s quarterly revenue was up 5.5% on a year-over-year basis. During the same quarter in the previous year, the business posted $0.39 EPS.
In other news, President Matthew Link sold 10,100 shares of the business’s stock in a transaction dated Thursday, May 2nd. The shares were sold at an average price of $62.00, for a total value of $626,200.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. 0.97% of the stock is currently owned by insiders.
Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Vanguard Group Inc. grew its position in shares of NuVasive by 2.3% during the 3rd quarter. Vanguard Group Inc. now owns 4,660,775 shares of the medical device company’s stock valued at $330,822,000 after buying an additional 103,225 shares during the last quarter. Fisher Asset Management LLC grew its position in shares of NuVasive by 1.2% during the 4th quarter. Fisher Asset Management LLC now owns 1,272,638 shares of the medical device company’s stock valued at $63,072,000 after buying an additional 15,359 shares during the last quarter. Norges Bank bought a new stake in shares of NuVasive during the 4th quarter valued at about $50,996,000. Macquarie Group Ltd. grew its position in shares of NuVasive by 17.7% during the 4th quarter. Macquarie Group Ltd. now owns 825,194 shares of the medical device company’s stock valued at $40,897,000 after buying an additional 124,224 shares during the last quarter. Finally, Geode Capital Management LLC grew its position in shares of NuVasive by 7.5% during the 4th quarter. Geode Capital Management LLC now owns 584,788 shares of the medical device company’s stock valued at $28,981,000 after buying an additional 40,600 shares during the last quarter.
NuVasive Company Profile
NuVasive, Inc, a medical device company, develops and markets minimally disruptive surgical products and procedurally integrated solutions for spine surgery. Its products focus on applications for spine fusion surgery, including ancillary products and services used to aid in the surgical procedure. The company's principal products include Maximum Access Surgery, a minimally disruptive surgical platform, which includes its software-driven nerve detection and avoidance systems, and intraoperative monitoring (IOM) services and support; MaXcess, an integrated split-blade retractor system; and various specialized implants and biologics.
Featured Story: Market Capitalization
Receive News & Ratings for NuVasive Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NuVasive and related companies with MarketBeat.com's FREE daily email newsletter.